Galapagos NV (GLPG) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Galapagos (GLPG) Q1 2026: $500M Capital Unlocked as Portfolio Shifts to Autoimmune Pipeline
May 07, 2026
-
Galapagos (GLPG) Q4 2025: €295M Operating Profit Signals Strategic Reset as Cell Therapy Wind-Down Lowers Cost Base
February 25, 2026
-
Galapagos (GLPG) Q3 2025: €204.8M Cell Therapy Impairment Forces Strategic Reset, Cash-Fueled BD Pivot Intensifies
November 07, 2025
-
Galapagos (GLPG) Q1 2025: €111M Restructuring Charge Signals Cell Therapy Pivot and SpinCo Split
July 06, 2025